Drugs / Bacillus calmette guerin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07424287 | Jul 2026 → Jun 2030 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus calmette guerin | “Bacillus calmette guerin (BCG) for injection.” NCT07424287 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07424287 ↗ |